Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 35
Filter
1.
Antiviral Res ; 209: 105485, 2023 01.
Article in English | MEDLINE | ID: mdl-36509208

ABSTRACT

The HBV core protein plays an integral role in multiple steps of the HBV lifecycle. Consequently, HBV core inhibitors interrupt multiple steps of the replication cycle, including blocking pgRNA encapsidation and prematurely disassembling existing nucleocapsids, thereby preventing them from transporting relaxed circular (rcDNA) to the nucleus for conversion to covalently closed circular DNA (cccDNA). ABI-H2158 is an HBV core inhibitor that advanced into Phase 2 clinical trials for the treatment of chronic hepatitis B virus infection (cHBV) but was discontinued due to hepatotoxicity. Here, the potency, selectivity, and mechanisms of action of ABI-H2158 were evaluated using a variety of cell-based assays. Antiviral activity was measured by quantifying intracellular or secreted HBV DNA, RNA, and antigens. ABI-H2158 inhibited HBV replication by blocking pgRNA encapsidation in induced HepAD38 cells (EC50 = 22 nM) and had similar potency in HBV-infected HepG2-NTCP cells (EC50 = 27 nM) and primary human hepatocytes (PHH) (EC50 = 41 nM). ABI-H2158 is a pan-genotypic HBV inhibitor, with EC50s ranging from 7.1 to 22 nM across HBV genotypes A-E. ABI-H2158 also potently blocked the formation of cccDNA in de novo HBV infections with EC50s of ∼200 nM in HepG2-NTCP and PHH assays. These results indicate ABI-H2158 has dual mechanisms of action, inhibiting both early and late steps of the HBV replication cycle.


Subject(s)
Hepatitis B virus , Hepatitis B, Chronic , Humans , Hepatitis B virus/genetics , Hepatitis B virus/metabolism , Hepatitis B, Chronic/drug therapy , Virus Replication/genetics , Hep G2 Cells , Hepatocytes , DNA, Circular/metabolism , DNA, Viral/genetics , DNA, Viral/metabolism
2.
ACS Med Chem Lett ; 13(6): 972-980, 2022 Jun 09.
Article in English | MEDLINE | ID: mdl-35707159

ABSTRACT

Allosteric HIV-1 integrase inhibitors (ALLINIs) have been of interest recently because of their novel mechanism of action. Strategic modifications to the C5 moiety of a class of 4-(4,4-dimethylpiperidinyl)-2,6-dimethylpyridinyl ALLINIs led to the identification of a tetrahydroisoquinoline heterocycle as a suitable spacer element to project the distal hydrophobic aryl ring. Subsequent optimization of the aryl substitutions identified 12 as an ALLINI with single-digit nanomolar inhibitory potency and low clearance across preclinical species. In preclinical toxicology studies with 12 in rats, lipid hepatocellular vacuolation was observed. Removal of the C6 methyl group resulted in GSK3839919 (22), which exhibited a reduced incidence and severity of lipid vacuolation in both in vitro assays and in vivo studies while maintaining the potency and pharmacokinetic (PK) properties of the prototype. The virology, PK, and toxicology profiles of 22 are discussed.

3.
Bioorg Med Chem ; 28(13): 115541, 2020 07 01.
Article in English | MEDLINE | ID: mdl-32389483

ABSTRACT

The design, synthesis and structure-activity relationships associated with a series of bridged tricyclic pyrimidinone carboxamides as potent inhibitors of HIV-1 integrase strand transfer are described. Structural modifications to these molecules were made in order to examine the effect on potency towards wild-type and clinically-relevant resistant viruses. The [3.2.2]-bridged tricyclic system was identified as an advantageous chemotype, with representatives exhibiting excellent antiviral activity against both wild-type viruses and the G140S/Q148H resistant virus that arises in response to therapy with raltegravir and elvitegravir.


Subject(s)
Antiviral Agents/chemical synthesis , HIV Infections/drug therapy , HIV Integrase Inhibitors/chemical synthesis , HIV Integrase/metabolism , Imidazoles/chemical synthesis , Pyrrolidinones/chemistry , Antiviral Agents/pharmacology , Drug Resistance, Viral/drug effects , Drug Therapy, Combination , HIV Integrase Inhibitors/pharmacology , HIV-1/drug effects , Humans , Imidazoles/pharmacology , Mutation , Quinolones/pharmacology , Raltegravir Potassium/pharmacology , Structure-Activity Relationship
4.
J Med Chem ; 63(5): 2620-2637, 2020 03 12.
Article in English | MEDLINE | ID: mdl-32081010

ABSTRACT

The standard of care for HIV-1 infection, highly active antiretroviral therapy (HAART), combines two or more drugs from at least two classes. Even with the success of HAART, new drugs with novel mechanisms are needed to combat viral resistance, improve adherence, and mitigate toxicities. Active site inhibitors of HIV-1 integrase are clinically validated for the treatment of HIV-1 infection. Here we describe allosteric inhibitors of HIV-1 integrase that bind to the LEDGF/p75 interaction site and disrupt the structure of the integrase multimer that is required for the HIV-1 maturation. A series of pyrazolopyrimidine-based inhibitors was developed with a vector in the 2-position that was optimized by structure-guided compound design. This resulted in the discovery of pyrazolopyrimidine 3, which was optimized at the 2- and 7-positions to afford 26 and 29 as potent allosteric inhibitors of HIV-1 integrase that exhibited low nanomolar antiviral potency in cell culture and encouraging PK properties.


Subject(s)
Allosteric Regulation/drug effects , HIV Integrase Inhibitors/chemistry , HIV Integrase Inhibitors/pharmacology , HIV-1/drug effects , Pyrazoles/chemistry , Pyrazoles/pharmacology , Pyridines/chemistry , Pyridines/pharmacology , Administration, Oral , Animals , Drug Discovery , HIV Infections/drug therapy , HIV Infections/virology , HIV Integrase/metabolism , HIV Integrase Inhibitors/administration & dosage , HIV Integrase Inhibitors/pharmacokinetics , Humans , Male , Molecular Docking Simulation , Pyrazoles/administration & dosage , Pyrazoles/pharmacokinetics , Pyridines/administration & dosage , Pyridines/pharmacokinetics , Rats, Sprague-Dawley
5.
Bioorg Med Chem Lett ; 30(3): 126784, 2020 02 01.
Article in English | MEDLINE | ID: mdl-31761656

ABSTRACT

A series of heterocyclic pyrimidinedione-based HIV-1 integrase inhibitors was prepared and screened for activity against purified integrase enzyme and/or viruses modified with the following mutations within integrase: Q148R, Q148H/G140S and N155H. These are mutations that result in resistance to the first generation integrase inhibitors raltegravir and elvitegravir. Based on consideration of drug-target interactions, an approach was undertaken to replace the amide moiety of the first generation pyrimidinedione inhibitor with azole heterocycles that could retain potency against these key resistance mutations. An imidazole moiety was found to be the optimal amide substitute and the observed activity was rationalized with the use of calculated properties and modeling. Rat pharmacokinetic (PK) studies of the lead imidazole compounds demonstrated moderate clearance and moderate exposure.


Subject(s)
Amides/chemistry , HIV Integrase Inhibitors/chemistry , HIV Integrase/chemistry , HIV-1/enzymology , Heterocyclic Compounds, 3-Ring/chemistry , Animals , Binding Sites , Catalytic Domain , Drug Resistance, Viral/drug effects , HIV Integrase/genetics , HIV Integrase/metabolism , HIV Integrase Inhibitors/metabolism , HIV Integrase Inhibitors/pharmacology , HIV-1/drug effects , Half-Life , Heterocyclic Compounds, 3-Ring/metabolism , Heterocyclic Compounds, 3-Ring/pharmacology , Humans , Molecular Dynamics Simulation , Mutation , Rats , Structure-Activity Relationship
6.
J Med Chem ; 62(3): 1348-1361, 2019 02 14.
Article in English | MEDLINE | ID: mdl-30609350

ABSTRACT

A series of 5,6,7,8-tetrahydro-1,6-naphthyridine derivatives targeting the allosteric lens-epithelium-derived-growth-factor-p75 (LEDGF/p75)-binding site on HIV-1 integrase, an attractive target for antiviral chemotherapy, was prepared and screened for activity against HIV-1 infection in cell culture. Small molecules that bind within the LEDGF/p75-binding site promote aberrant multimerization of the integrase enzyme and are of significant interest as HIV-1-replication inhibitors. Structure-activity-relationship studies and rat pharmacokinetic studies of lead compounds are presented.


Subject(s)
HIV Integrase Inhibitors/pharmacology , HIV-1/drug effects , Naphthyridines/pharmacology , Allosteric Site , Crystallography, X-Ray , HIV Infections/drug therapy , HIV Integrase Inhibitors/chemistry , HIV Integrase Inhibitors/therapeutic use , HIV-1/enzymology , HIV-1/physiology , Humans , Naphthyridines/chemistry , Naphthyridines/therapeutic use , Virus Replication/drug effects
7.
Front Plant Sci ; 9: 970, 2018.
Article in English | MEDLINE | ID: mdl-30123225

ABSTRACT

9-cis-epoxycarotenoid dioxygenase (NCED) is a key enzyme involved in the biosynthesis of abscisic acid (ABA), which is associated with drought tolerance in plants. An osmotic-inducible VaNCED1 gene was isolated from a drought-resistant cultivar of Vitis amurensis and constitutively overexpressed in a drought-sensitive cultivar of Vitis vinifera. Transgenic plants showed significantly improved drought tolerance, including a higher growth rate and better drought resistant under drought conditions, compared to those of wild-type (WT) plants. After water was withheld for 50 days, the upper leaves of transgenic plants remained green, whereas most leaves of WT plants turned yellow and fell. Besides the increase in ABA content, overexpression of VaNCED1 induced the production of jasmonic acid (JA) and accumulation of JA biosynthesis-related genes, including allene oxide cyclase (AOC) and 12-oxophytodienoate reductase (OPR3). Moreover, transgenic plants possessed advantageous physiological indices, including lower leaf stomatal density, lower photosynthesis rate, and lower accumulation of proline and superoxide dismutase (SOD), compared to those of WT plants, indicating increased resistance to drought stress. Quantitative real time polymerase chain reaction (RT-qPCR) analysis revealed that overexpression of VaNCED1 enhanced the expression of drought-responsive genes, such as ABA-responsive element1 (ABRE1), ABRE binding factors 2 (ABF2), plasma membrane intrinsic proteins 2 (PIP2), C-repeat/DRE-Binding Factor 4 (VvCBF4) and ABA-insensitive 5 (ABI5). Although the development of transgenic plants was delayed by 4 months than WT plants, because of seed dormancy and abnormal seedlings, the surviving transgenic plants provided a solid method for protection of woody plants from drought stress.

8.
Bioorg Med Chem Lett ; 28(12): 2124-2130, 2018 07 01.
Article in English | MEDLINE | ID: mdl-29779976

ABSTRACT

BMS-707035 is an HIV-1 integrase strand transfer inhibitor (INSTI) discovered by systematic optimization of N-methylpyrimidinone carboxamides guided by structure-activity relationships (SARs) and the single crystal X-ray structure of compound 10. It was rationalized that the unexpectedly advantageous profiles of N-methylpyrimidinone carboxamides with a saturated C2-substitutent may be due, in part, to the geometric relationship between the C2-substituent and the pyrimidinone core. The single crystal X-ray structure of 10 provided support for this reasoning and guided the design of a spirocyclic series 12 which led to discovery of the morpholino-fused pyrimidinone series 13. Several carboxamides derived from this bicyclic scaffold displayed improved antiviral activity and pharmacokinetic profiles when compared with corresponding spirocyclic analogs. Based on the excellent antiviral activity, preclinical profiles and acceptable in vitro and in vivo toxicity profiles, 13a (BMS-707035) was selected for advancement into phase I clinical trials.


Subject(s)
Anti-HIV Agents/pharmacology , Drug Discovery , HIV Integrase Inhibitors/pharmacology , HIV Integrase/metabolism , HIV/drug effects , Pyrimidines/pharmacology , Pyrimidinones/pharmacology , Thiazines/pharmacology , Anti-HIV Agents/chemical synthesis , Anti-HIV Agents/chemistry , Dose-Response Relationship, Drug , HIV Integrase Inhibitors/chemical synthesis , HIV Integrase Inhibitors/chemistry , Humans , Microbial Sensitivity Tests , Molecular Structure , Pyrimidines/chemical synthesis , Pyrimidines/chemistry , Pyrimidinones/chemical synthesis , Pyrimidinones/chemistry , Structure-Activity Relationship , Thiazines/chemical synthesis , Thiazines/chemistry
9.
Bioorg Med Chem Lett ; 27(23): 5100-5108, 2017 12 01.
Article in English | MEDLINE | ID: mdl-29100802

ABSTRACT

Overcoming poor solubility is a significant issue in drug discovery. The most common solution is to replace carbon atoms with polar heteroatoms such as N and O or by attaching a solubilizing appendage. This approach can lead to other issues such as poor activity and PK or the increased risk for toxicity. However, there are more subtle structural changes which can be employed that lead to an increase in solubility. These include, excising hydrophobic groups which do not efficiently contribute to binding, modifying stereo- and regiochemistry, increasing or decreasing the degree of unsaturation or adding small hydrophobic groups such as fluorine or methyl.


Subject(s)
Pharmaceutical Preparations/chemistry , Water/chemistry , Carbon/chemistry , Drug Discovery , Hydrogen-Ion Concentration , Hydrophobic and Hydrophilic Interactions , Pharmaceutical Preparations/metabolism , Solubility
10.
Stat Med ; 35(14): 2467-78, 2016 06 30.
Article in English | MEDLINE | ID: mdl-26728099

ABSTRACT

Meta-analysis of clinical trials is a methodology to summarize information from a collection of trials about an intervention, in order to make informed inferences about that intervention. Random effects allow the target population outcomes to vary among trials. Since meta-analysis is often an important element in helping shape public health policy, society depends on biostatisticians to help ensure that the methodology is sound. Yet when meta-analysis involves randomized binomial trials with low event rates, the overwhelming majority of publications use methods currently not intended for such data. This statistical practice issue must be addressed. Proper methods exist, but they are rarely applied. This tutorial is devoted to estimating a well-defined overall relative risk, via a patient-weighted random-effects method. We show what goes wrong with methods based on 'inverse-variance' weights, which are almost universally used. To illustrate similarities and differences, we contrast our methods, inverse-variance methods, and the published results (usually inverse-variance) for 18 meta-analyses from 13 Journal of the American Medical Association articles. We also consider the 2007 case of rosiglitazone (Avandia), where important public health issues were at stake, involving patient cardiovascular risk. The most widely used method would have reached a different conclusion. © 2016 The Authors. Statistics in Medicine published by John Wiley & Sons Ltd.


Subject(s)
Clinical Trials as Topic/statistics & numerical data , Meta-Analysis as Topic , Biostatistics , Cardiovascular Diseases/etiology , Diabetes Mellitus, Type 2/drug therapy , Humans , Hypoglycemic Agents/adverse effects , Models, Statistical , Risk , Risk Factors , Rosiglitazone , Thiazolidinediones/adverse effects
11.
Bioorg Med Chem Lett ; 25(3): 717-20, 2015 Feb 01.
Article in English | MEDLINE | ID: mdl-25529736

ABSTRACT

Integration of viral DNA into the host cell genome is an obligatory process for successful replication of HIV-1. Integrase catalyzes the insertion of viral DNA into the target DNA and is a validated target for drug discovery. Herein, we report the synthesis, antiviral activity and pharmacokinetic profiles of several C2-carbon-linked heterocyclic pyrimidinone-4-carboxamides that inhibit the strand transfer step of the integration process.


Subject(s)
Amides/chemistry , HIV Integrase Inhibitors/chemical synthesis , HIV Integrase/chemistry , HIV-1/enzymology , Amides/chemical synthesis , Amides/pharmacokinetics , Animals , HIV Integrase/metabolism , HIV Integrase Inhibitors/chemistry , HIV Integrase Inhibitors/pharmacokinetics , HIV-1/drug effects , Half-Life , Heterocyclic Compounds/chemistry , Humans , Male , Pyrimidines/chemistry , Rats , Rats, Sprague-Dawley , Structure-Activity Relationship
12.
Expert Opin Drug Discov ; 9(12): 1421-33, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25226793

ABSTRACT

INTRODUCTION: Physiochemical drug properties, such as aqueous solubility are considered to be a major factor in determining the ultimate success or failure of experimental agents. Solubility is important because it determines the maximum dose which can be taken up. As the size and hydrophobicity of drug candidates has increased over the years, poor solubility has become a more prevalent issue. Recent examples from the literature show that an improved understanding of the relationship between molecular structure and solubility allows this issue to be approached using rational design. AREAS COVERED: This review provides selected examples from the recent drug discovery literature that demonstrate various tactics, which have been applied successfully towards improving drug solubility. The examples that were selected demonstrate the underlying principles behind aqueous solubility, such as hydrophobicity and crystalline stability. EXPERT OPINION: From a strategic point of view, improving the solubility of a compound should be straightforward because it can be accomplished by simply reducing hydrophobicity or crystalline stability. However, the structural elements and physical properties which control solubility also influence potency, pharmacokinetics and toxicity. Furthermore, there are practical aspects such as the quantity and quality of solubility-related data, which hamper the development of structure-solubility relationships. Given that poor aqueous solubility remains a primary issue in drug discovery, there is a continuous need for novel methods to overcome it.


Subject(s)
Algorithms , Pharmaceutical Preparations/chemistry , Water/chemistry , Drug Discovery , Solubility
13.
Org Lett ; 16(17): 4444-7, 2014 Sep 05.
Article in English | MEDLINE | ID: mdl-25140991

ABSTRACT

An operationally simple chemoselective transfer hydrogenation of alkenes using ruthenium metathesis catalysts is presented. Of great practicality, the transfer hydrogenation reagents can be added directly to a metathesis reaction and effect hydrogenation of the product alkene in a single pot at ambient temperature without the need to seal the vessel to prevent hydrogen gas escape. The reduction is applicable to a range of alkenes and can be performed in the presence of aryl halides and benzyl groups, a notable weakness of Pd-catalyzed hydrogenations. Scope and mechanistic considerations are presented.


Subject(s)
Alkenes/chemistry , Catalysis , Combinatorial Chemistry Techniques , Cyclization , Hydrogenation , Molecular Structure , Ruthenium/chemistry
14.
Expert Opin Ther Pat ; 21(8): 1173-89, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21599420

ABSTRACT

INTRODUCTION: The use of inhibitors of HIV-1 integrase for treating HIV-1 infection has proven to be very beneficial. Raltegravir, a strand transfer inhibitor, has been approved for use both as a first-line therapy and in treatment-experienced patients. A second compound in this class, elvitegravir, is in Phase III clinical trials and is being developed as part of a once daily fixed dose combination pill. With widespread use of raltegravir, viral resistance has emerged with surprising facility. Attempts to use raltegravir on a once daily dosing regimen have been unsuccessful whilst elvitegravir cannot be delivered daily without the aid of a pharmacokinetic (PK)-enhancing agent. Thus, there is a need for second generation compounds to address these issues. AREAS COVERED: Patent applications claiming compounds useful as inhibitors of HIV-1 integrase are reviewed in this paper, along with compounds related to the strand transfer inhibitors. EXPERT OPINION: The field appears to be more focused on developing compounds which address the issues identified for the first generation compounds, raltegravir and elvitegravir. Patent activity around new strand transfer inhibitors claims compounds active against first generation resistant mutations and having PK profiles suitable for daily dosing. Advancements in this area have been rapid and several compounds described in these patent applications are currently in clinical trials. Bolstered by recent mechanistic discoveries, compounds inhibiting processes other than strand transfer have begun to emerge. It is foreseeable that a second generation integrase inhibitor could be approved for treatment in the coming years.


Subject(s)
HIV Infections/drug therapy , HIV Integrase Inhibitors/therapeutic use , HIV Integrase/metabolism , HIV-1/drug effects , Animals , Drug Resistance, Viral , HIV Infections/virology , HIV Integrase Inhibitors/administration & dosage , HIV Integrase Inhibitors/chemistry , HIV Integrase Inhibitors/pharmacokinetics , HIV-1/enzymology , Humans , Patents as Topic , Structure-Activity Relationship
15.
Vet Radiol Ultrasound ; 51(3): 338-43, 2010.
Article in English | MEDLINE | ID: mdl-20469559

ABSTRACT

We have observed focal skeletal muscle uptake of 99mTechnetium-hydroxymethylene diphosphonate (Tc-HDP), which could mimic a tibial lesion, in horses following peroneal nerve blocks. To characterize this observation further, 45 bone phase scintigrams were performed in 12 horses undergoing peroneal nerve blocks. Scans were performed before, and 1, 3, 7, and 14 days postblock. The superficial and deep branches of the peroneal nerve were blocked by injecting 10 ml of 2% mepivacaine in one limb and 20 ml in the other. Images were evaluated for uptake at the block site and uptake likely to mimic a tibial lesion. Regions of interest were placed over the block site and distal tibia. Count density ratios were used to estimate change in uptake intensity over time. The overall proportion affected was 0.52 (95% confidence interval [CI], 0.36-0.68; P < 0.001) 1 day postblock and 0.24 (95% CI, 0.13-0.40; P = 0.005) 3 days postblock. The overall proportion likely to mimic a tibial lesion was 0.19 (95% CI, 0.09-0.33; P < 0.001) 1 day postblock and 0.21 (95% CI, 0.09-0.40; P = 0.005) 3 days postblock. Focal skeletal muscle uptake was seen in only one horse 7 days postblock. Increased uptake intensity was associated with higher local anesthetic dose (P = 0.042). Peroneal nerve blocks cause focal skeletal muscle uptake of 99mTc-HDP on bone phase scintigraphy. This occurs in approximately 50% of blocked limbs and can mimic a tibial lesion on the lateral view in approximately 20% of blocked limbs.


Subject(s)
Horses , Muscle, Skeletal/diagnostic imaging , Nerve Block/veterinary , Peroneal Nerve , Radiopharmaceuticals , Technetium Tc 99m Medronate/analogs & derivatives , Animals , Female , Male , Muscle, Skeletal/innervation , Radionuclide Imaging
16.
J Comb Chem ; 12(1): 84-90, 2010.
Article in English | MEDLINE | ID: mdl-19902958

ABSTRACT

A novel series of HIV-1 integrase inhibitors were identified from a 100 member (4R(1) x 5R(2) x 5R(3)) library of pyrrolidinedione amides. A solid-phase route was developed which facilitates the simultaneous variation at R(1), R(2), and R(3) of the pyrrolidinedione scaffold. The resulting library samples were assayed for HIV-1 integrase activity and analyzed to determine the R(1), R(2), and R(3) reagent contributions towards the activity.


Subject(s)
Drug Design , HIV Integrase Inhibitors/chemical synthesis , HIV-1/drug effects , Succinimides/chemical synthesis , Combinatorial Chemistry Techniques/methods , HIV Integrase Inhibitors/pharmacology , Humans , Inhibitory Concentration 50 , Molecular Structure , Succinimides/chemistry , Succinimides/pharmacology
17.
Curr Opin Investig Drugs ; 10(2): 129-36, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19197790

ABSTRACT

Integrase (IN) inhibitors have proven to be highly beneficial in the treatment of HIV infection. The recently approved inhibitor, raltegravir, the phase III clinical trials compound elvitegravir, and all other agents reported to be in clinical trials bind to the active site of IN and share the same mechanism of action. There is a high probability for the development of cross resistance among these compounds. Therefore, drugs targeting alternative mechanisms and binding sites on IN are desired. Two potential sites for inhibiting the enzyme have been disclosed recently. The first site is located in the catalytic core domain and is used by the enzyme to bind the host protein lens epithelium-derived growth factor. The second site was identified by the selective covalent trapping of pyridoxal phosphate to the C-terminal domain of the enzyme. The targeting of these sites as a potential novel approach for inhibiting HIV IN is reviewed.


Subject(s)
HIV Integrase Inhibitors/pharmacology , HIV Integrase/metabolism , Binding Sites , Catalytic Domain , Clinical Trials, Phase III as Topic , Forecasting , HIV Integrase/chemistry , HIV Integrase Inhibitors/chemistry , HIV Integrase Inhibitors/therapeutic use , Humans , Intercellular Signaling Peptides and Proteins/metabolism , Intercellular Signaling Peptides and Proteins/therapeutic use , Models, Molecular , Molecular Structure , Protein Structure, Tertiary , Pyridoxal Phosphate/chemistry , Pyridoxal Phosphate/metabolism , Pyridoxal Phosphate/therapeutic use
18.
Biochemistry ; 47(51): 13481-8, 2008 Dec 23.
Article in English | MEDLINE | ID: mdl-18991395

ABSTRACT

Specific HIV integrase strand transfer inhibitors are thought to bind to the integrase active site, positioned to coordinate with two catalytic magnesium atoms in a pocket flanked by the end of the viral LTR. A structural role for the 3' terminus of the viral LTR in the inhibitor-bound state has not previously been examined. This study describes the kinetics of binding of a specific strand transfer inhibitor to integrase variants assembled with systematic changes to the terminal 3' adenosine. Kinetic experiments are consistent with a two-step binding model in which there are different functions for the terminal adenine base and the terminal deoxyribose sugar. Adenine seems to act as a "shield" which retards the rate of inhibitor association with the integrase active site, possibly by acting as an internal competitive inhibitor. The terminal deoxyribose is responsible for retarding the rate of inhibitor dissociation, either by sterically blocking inhibitor egress or by a direct interaction with the bound inhibitor. These findings further our understanding of the details of the inhibitor binding site of specific strand transfer inhibitors.


Subject(s)
HIV Integrase Inhibitors/pharmacology , HIV Integrase/genetics , HIV Long Terminal Repeat/genetics , 3' Untranslated Regions , Adenosine/chemistry , Binding, Competitive , Catalytic Domain , Chemistry, Pharmaceutical/methods , HIV/genetics , HIV Integrase/metabolism , Kinetics , Models, Chemical , Models, Molecular , Molecular Conformation , Protein Binding , Temperature
19.
Expert Opin Ther Targets ; 12(8): 949-67, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18620518

ABSTRACT

BACKGROUND: There is a growing body of literature describing the etiology of autism spectrum disorders (ASD). Some of the targets suggested belong to neurochemical transmitter pathways implicated in the behavior and motivation reward pathway. OBJECTIVE: To examine data linking potential targets to ASD and the feasibility of developing drugs targeting these pathways. While the inhibitors are mostly being developed for other indications, it is beneficial to examine them to determine the responsiveness of the targets to small-molecule modulation. METHODS: A search in Medline and Scifinder for articles concerning relevant targets in the context of ASD and their relation to the reward signaling pathway. RESULTS: There is evidence suggesting that behaviors controlled by these targets are related to behaviors exhibited by individuals with ASD. The targets appear to be involved in neurotransmitter pathways controlling motivation and reward, further implicating this system in ASD. Sufficient research has been conducted to identify lead compounds for discovering agents for treatment of ASD.


Subject(s)
Autistic Disorder/drug therapy , Neurotransmitter Agents/therapeutic use , Signal Transduction/drug effects , Animals , Autistic Disorder/classification , Autistic Disorder/epidemiology , Humans , Motivation , Reward
20.
J Biol Chem ; 283(35): 23599-609, 2008 Aug 29.
Article in English | MEDLINE | ID: mdl-18577511

ABSTRACT

In this study, eight different HIV-1 integrase proteins containing mutations observed in strand transfer inhibitor-resistant viruses were expressed, purified, and used for detailed enzymatic analyses. All the variants examined were impaired for strand transfer activity compared with the wild type enzyme, with relative catalytic efficiencies (k(p)/K(m)) ranging from 0.6 to 50% of wild type. The origin of the reduced strand transfer efficiencies of the variant enzymes was predominantly because of poorer catalytic turnover (k(p)) values. However, smaller second-order effects were caused by up to 4-fold increases in K(m) values for target DNA utilization in some of the variants. All the variants were less efficient than the wild type enzyme in assembling on the viral long terminal repeat, as each variant required more protein than wild type to attain maximal activity. In addition, the variant integrases displayed up to 8-fold reductions in their catalytic efficiencies for 3'-processing. The Q148R variant was the most defective enzyme. The molecular basis for resistance of these enzymes was shown to be due to lower affinity binding of the strand transfer inhibitor to the integrase complex, a consequence of faster dissociation rates. In the case of the Q148R variant, the origin of reduced compound affinity lies in alterations to the active site that reduce the binding of a catalytically essential magnesium ion. Finally, except for T66I, variant viruses harboring the resistance-inducing substitutions were defective for viral integration.


Subject(s)
DNA, Viral/chemistry , Drug Resistance, Viral/drug effects , HIV Integrase Inhibitors/chemistry , HIV Integrase/chemistry , HIV-1/enzymology , Mutation, Missense , Amino Acid Substitution , Catalysis , Cell Line , DNA, Viral/genetics , DNA, Viral/metabolism , Drug Resistance, Viral/genetics , HIV Integrase/genetics , HIV Integrase/metabolism , HIV Long Terminal Repeat/physiology , HIV-1/genetics , Humans , Kinetics , Virus Integration/drug effects , Virus Integration/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...